



## 2023 Plenary Sessions Team Disclosures

The following types of relationships may be deemed relevant include:

1. Advisor or Review Panel Member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property/Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

*All of the relevant financial relationships listed for the plenary sessions have been mitigated.*

### **Samar Aboulenain, MBBCH**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

### **Accelerating Medicines Partnership Program (AMP RA/SLE) Network**

**0722.** Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of

Aryl Hydrocarbon Receptor and Type I Interferon

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ifeoluwakiisi Adejorin, BS**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Amita Aggarwal, MD, MBBS, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Pooneh Akhavan, MD, FRCPC, MSc**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sibel Aydin, MD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): AbbVie, 5, 6, Celgene, 5, 6, Eli Lilly, 5, 6, Janssen, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, UCB, 5, 6*

**Rebecca Baer, MPH**

**0722.** Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Joshua Baker, MD, MS**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): Bristol-Myers Squibb(BMS), 2, Burns-White, LLC, 2, CorEvitas, LLC, 2, Pfizer, 2, Cumberland Pharma, 2, Horizon Pharmaceuticals, 5*

**Mohammad Bardi, MD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Susan Barr, MD, FRCPC, MSc**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Montana Barrett, BS**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Hassan Behloui, PhD**

**1584.** Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Richard Bell, PhD**

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Isaac Benque**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sasha Bernatsky, MD, PhD**

**1584.** Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Betsy Barnes, PhD**

**13M123.** Plenary II (1579–1584)

Role: Plenary Moderator, Plenary Reviewer

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Kartik Bhamidipati, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Leishangthem Bidyalaxmi, PhD**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Raphael Borie, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Idris Boudhabhay, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Teri Bowman, HT ASCP**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sabrina Bracero**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Michael Brenner, MD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): 4FO Ventures, 2, GlaxoSmithKlein(GSK), 2, Mestag Therapeutics, 2, 11, Third Rock Ventures, 2*

**Ewurama Cann, BS**

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Grant Cannon, MD**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ye Cao, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Junning Case, MA**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Alessandra Ida Celia, MD**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Christina Chambers, PhD, MPH**

**0722.** Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Role: Author

*Disclosure(s): Amgen, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5, Genzyme Sanofi-Aventis, 5, Gerber Foundation, 5, Gilead, 5, GlaxoSmithKline, 5, Hoffman La-Roche-Genentech, 5, Janssen Pharmaceuticals, 5, Leo Pharma, 5, Novartis, 5, Pfizer, Inc., 5, Regeneron, 5, S*

**Kar Li Kelly Chan, FRCP**

**2429.** Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Lin Chen**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Hyon K. Choi, MD, DrPH**

**1579.** Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

**2428.** Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Role: Author

*Disclosure(s): Ani, 2, Horizon, 2, 5, LG, 2, Protalix, 2, Shanton, 2.*

**Jaehyuk Choi, MD, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Daniel Clauw, MD**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): AbbVie, 2, Allergan, 2, Aptinyx, 2, Eli Lilly, 2, Fasken Martineau DuMoulin LLP, 6, H. Lundbeck A/S, 2, Heron Therapeutics, Inc, 2, Kellogg, Hansen, Todd, Figel & Frederick, 6, Marks & Clerk Law LLP, 6, Neumentum, Inc., 2, Nix Patterson LLP, 6, Pfizer, 2,*

**Shirley Cohen-Mekelburg, MD, MSc**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Karen Costenbader, MD, MPH**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5*

**Thomas Crépin, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Jeffrey R. Curtis, MD, MS, MPH**

**1584.** Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): AbbVie, 2, 5, Amgen, 2, 5, BMS, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Genentech, 2, 5, Janssen, 2, 5, Pfizer, 2, 5, Roche, 2, 5, UCB Pharma, 2, 5*

**Anne Davidson, MBBS, FRACP**

**14T127.** Plenary III (2425–2430)

Role: Plenary Moderator, Plenary Reviewer

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Xiaoyue Deng, PhD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Janeve Desy, MD, MEHP, FRCPC, RDMS**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Varun Dhir, MD, MBBS, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Rashmi Dhital, MD**

**0722.** Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Laura Donlin, PhD**

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Role: Author

*Disclosure(s): Bristol-Myers Squibb(BMS), 2, Stryker, 2*

**Christopher Dunn, MS**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Gabby Dyson, BS**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Lihi Eder, MD, PhD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): AbbVie, 2, 5, Eli Lilly, 2, 5, Fresenius Kabi, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sandoz, 5, UCB, 2, 5*

**Bryant England, MD, PhD, RhMSUS**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Presenting Author

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): Boehringer-Ingelheim, 2, 5*

**Andrea Fava, MD**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): Annexon Biosciences, 2, Sanofi, 1*

**Tracy Frech, MD, MS**

**14T127.** Plenary III (2425–2430)

Role: Plenary Moderator, Plenary Reviewer

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ce Gao, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yuqing Gao, MS**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Michael George, MD, MSc**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): AbbVie/Abbott, 2, GlaxoSmithKlein(GSK), 5, Janssen, 5*

**Mathieu Gerfaud-Valentin, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Jean-Baptiste Gouin, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Tiphaine Goulenok**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Mary-Jane Guerry, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with



Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Monica Guma, MD, PhD**

**0722.** Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ranjan Gupta, MD, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Eric Hachulla, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Nicholas Hanebutt, BS**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Rodney Hayward, MD**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Alice Horisberger, MD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Audra Horomanski, MD**

**2425.** Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Judd Hultquist, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sébastien Humbert, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Lionel Ivashkiv, MD**

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Avinash Jain, MD Medicine**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sanjay Jain, MBBS MD DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Matlock Jeffries, MD, FACP, FACR**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Dana Jerome, MD, FRCPC, MEd**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Tate Johnson, MD**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Anna Helena Jonsson, MD, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**April Jorge, MD**

**1579.** Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Gurjit S. Kaeley, MBBS, RhMSUS, MRCP**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): Abbvie, 5, Gilead, 5, Janssen, 5*

**Kenneth Kalunian, MD, FACP**

**0722.** Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Role: Author

*Disclosure(s): AbbVie/Abbott, 2, Amgen, 5, AstraZeneca, 2, Aurinia, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EquilliumBio, 2, Genentech, 2, Gilead, 2, Janssen, 2, KezarBio, 1, Merck/MSD, 2, Novartis, 2, Pfizer, 2, Remegene, 2, Roche, 2, UCB, 5*

**Alexandre Karras, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): AstraZeneca, 6, GlaxoSmithKlein(GSK), 4, Novartis, 2, Pfizer, 6*

**Shideh Kazerounian, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Joshua Keegan, BS**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Philippe Kerschen, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Meeshal Khan, MD**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Aastha Khullar, MSc**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once

Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**H. Myra Kim, PhD**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sharon Kolasinski, MD**

**12S122.** Plenary I (0722–0726)

Role: Plenary Moderator, Plenary Reviewer

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Minna Kohler, MD, RhMSUS**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): Mymee, 2, Springer Publications, 9*

**Suppawat Kongthong**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sahil Koppikar, MD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Adam Kovacs-Litman, MD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Shirley Lake, RhMSUS**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Amit Lakhanpal, MD, PhD**

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Maggie Larche, PhD, MBChB**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Calvin Law**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Céline Lebas, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**James Lederer, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Meng Tao Li, MD, PhD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yuhong Li**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Zhihan Li**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Kehuan Lin, MS**

**2428.** Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Na Lu, MPH**

**2428.** Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Christopher Lyddell, MD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Irene W. Y. Ma, MD, PhD, FRCPC, FACP**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Wai Han Ma, FRCR**

**2429.** Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Silvia Malvica, MD**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ramesh Manthri**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Elena Massarotti, MD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Natalie McCormick, PhD, MSc**

**1579.** Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

**2428.** Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Kevin McLaughlin, MBChB, MRCP, PhD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sarah Melboucy-Belkhir, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Arielle Mendel, MD, FRCPC, MSc**

**1584.** Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Rafik Mesbah, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ted R. Mikuls, MD**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9*

**Hana Minsky**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Cindy Miranda, MS**

**1581.** Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Chi Chiu Mok, MD, FRCP**

**2429.** Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sophie Nagle, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Shankar Naidu, MBBS MD DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Antoine Néel**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Hung Nguyen, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yann Nguyen, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Gabriel Nigrovic**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Roderau Outh, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Venkatesh S. Pai, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Diana Pena Nunez, MD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*



**Chris Penney, MD**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Michelle Petri, MD, MPH**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): Alexion, 1, Amgen, 1, AnaptysBio, 1, Annexon Bio, 1, Argenx, 1, Arhros-Focus Med/Ed, 6, AstraZeneca, 1, 5, Aurinia, 1, 5, 6, Axdev, 1, Biogen, 1, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CVS Health, 1, Eli Lilly, 1, 5, Emergent Biosolut*

**Devarasetti Phani Kumar, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Arundhati Pillai**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Janet Pope, MD, FRCPC, MPH**

**13M123.** Plenary II (1579–1584)

Role: Plenary Moderator, Plenary Reviewer

*Disclosure: AbbVie/Abbott, 2 (Ongoing), 5 (Ongoing); Amgen, 2 (Ongoing); AstraZeneca, 2 (Ongoing); Boehringer Ingelheim, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Eli Lilly, 2 (Ongoing), 5 (Ongoing); Fresenius Kabi, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Janssen, 2 (Ongoing); Mallinckrodt, 2 (Ongoing); Novartis, 2 (Ongoing); Organon, 2 (Ongoing); Pfizer, 2 (Ongoing); Sandoz, 2 (Ongoing); Viartis, 2 (Ongoing)*

**Maria Powell, MD, FRCPC, MSc**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Chandra Bhushan Prasad, MD, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sonia Presti, BS**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Xavier Puéchal, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Gregory Pugnet, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Junyan Qian, MD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Deepak Rao, MD, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): AstraZeneca, 2, Bristol-Myers Squibb, 2, 5, GlaxoSmithKlein(GSK), 2, Hifibio, 2, Janssen, 5, Merck, 5, Scipher Medicine, 2.*

**Amadeia Rector, MPH**

**2425.** Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Jorge Rojas Jr, MS**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Avi Rosenberg, MD, PhD**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Punyasha Roul, MS**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Priya Saini, MSc**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Brian Sauer, PhD**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Harlan Sayles, MS**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Aman Sharma, MD, MBBS, FRCP**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Shefali Sharma, MD**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Gary Shaw, DrPH**

**2425.** Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Julia Simard, ScD**

**2425.** Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Daimon Simmons, MD, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of

Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Viktoriya Skidanova**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**John Sowerby, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**STARS BWH**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): Mestag Therapeutics, 2*

**Michael Stein, MD, FRCPC**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Benjamin Subran, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Jeremy Sussman, MD, MSc**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Benjamin Terrier, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Presenting Author

*Disclosure(s): AstraZeneca, 5, CSL Vifor, 2, GlaxoSmithKlein(GSK), 2*

**Koshy Nithin Thomas, MD, DM**

**1583.** Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Steven Thomson, MD, MSc**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Dimitri Titeca-Beauport, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Sau Mei Tse, MBChB**

**2429.** Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yurdagul Uzunhan, MD, PhD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Evelyne Vinet, MD, PhD, FRCPC**

**1584.** Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Stéphane Vinzio, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Vanessa Wacleche, PhD**

**1580.** CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Akbar Waljee, MD, MSc**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Beth Wallace, MD**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Presenting Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Qian Wang, MD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ranran Wang, PhD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Gerald F.M. Watts, MS**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Kevin Wei, MD, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): 10X Genomics, 5, capital one, 6, Gilead sciences, 5, horizon therapeutics, 6, Mestag, 2.*

**Douglas White, MD, PhD**

**12S122.** Plenary I (0722–0726)

Role: Plenary Moderator, Plenary Reviewer

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Wyndy Wiitala, PhD**

**2430.** Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Juliette Woessner, MD**

**0725.** Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Chao Yang, PhD**

**0724.** Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Xiaoping Yang, MD, PhD**

**2427.** Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yangyuna Yang, PhD, MBBS**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Ashley Yip, MD, BSc**

**0726.** Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Chio Yokose, MD, MSc**

**1579.** Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

**2428.** Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Fang Yu, PhD**

**1582.** Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Tianyi Yuan, PhD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Xiaofeng Zeng, MD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Fan Zhang, PhD**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yuqing Zhang, DSc**

**1579.** Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic

Lupus Erythematosus

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Yuqing Zhang, DSc**

**2428.** Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Jiuliang Zhao, PhD**

**0723.** Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Baijun Zhou, MHS**

**1579.** Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*

**Zhu Zhu, MS**

**2426.** The Role of  $\beta$ -catenin in Synovial Lining Fibroblast Differentiation

Role: Author

*Disclosure(s): No financial relationships with ineligible companies to disclose*